| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5705531 | Ophthalmology | 2016 | 9 Pages |
Abstract
Visual acuity outcomes at 12 months did not differ between ranibizumab and aflibercept used for nAMD in this large observational study, nor was a difference in treatment frequency found.
Keywords
CNVFRBLOCFnAMDRCTPRNIQRRandomized controlled trialstandard deviationVisual acuitytreat and extendneovascular age-related macular degenerationpro re natachoroidal neovascular membraneconfidence intervalVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)interquartile rangelast observation carried forward
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Mark C. MBBS, PhD, Vuong PhD, Vincent MD, PhD, Jennifer J. MBBS (Hons), Nigel MBBS, Daniel MD, PhD,